Related references
Note: Only part of the references are listed.Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient
Daniel Schmidt et al.
NEUROENDOCRINOLOGY (2018)
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors
Atsuko Kasajima et al.
ENDOCRINE-RELATED CANCER (2018)
Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort
Matteo Giaj Levra et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
Andrew Sharabi et al.
ONCOLOGIST (2017)
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor
Kentaro Inamura et al.
CANCER MEDICINE (2017)
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Victoria E. Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Immunotherapy and patients treated for cancer with microsatellite instability
Raphael Colle et al.
BULLETIN DU CANCER (2017)
Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report
Justin Kenneth Ugwu et al.
CASE REPORTS IN ONCOLOGY (2017)
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study
Namrata Vijayvergia et al.
BRITISH JOURNAL OF CANCER (2016)
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
Pedro N. Aguiar et al.
IMMUNOTHERAPY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
Yangwei Fan et al.
ONCOTARGETS AND THERAPY (2016)
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
Mack Y. Su et al.
PLOS MEDICINE (2016)
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Seung Tae Kim et al.
JOURNAL OF CANCER (2016)
Metastatic Merkel cell carcinoma response to nivolumab
Frances M. Walocko et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
Claudia Vollbrecht et al.
BRITISH JOURNAL OF CANCER (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade
Ignacio Melero et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity
Nora Sahnane et al.
ENDOCRINE-RELATED CANCER (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Raju R. Raval et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity
Alan G. Ramsay
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Julie R. Brahmer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Loss of Expression of DNA Mismatch Repair Proteins Is Rare in Pancreatic and Small Intestinal Neuroendocrine Tumors
Thomas Arnason et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2011)
T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases
Steven C. Katz et al.
HPB (2010)
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
Sofia Vikman et al.
ACTA ONCOLOGICA (2009)
Clinical Implications of Microsatellite Instability and MLH1 Gene Inactivation in Sporadic Insulinomas
Mei Mei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients
Sowa Vikman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers
Matthias Schott
ENDOCRINE-RELATED CANCER (2006)
Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors
M Kidd et al.
CANCER (2005)
Expression of HLA class I/II antigens and T cell immune response in human neuroendocrine tumors of the pancreas
E Ryschich et al.
TISSUE ANTIGENS (2003)
Share Paper
